Yong Dai Net Worth

Yong Dai biography

Dr. Yong Dai Ph.D. serves as Chief Technology Officer of the Company. He joined us in March 2018 as the Senior Vice President of Gene Therapy, bringing more than 17 years of biotechnology industry experience focused on bioprocess development, chemistry, manufacturing and controls, or CMC, good manufacturing process, process validation and regulatory submissions, including extensive work with gene therapy drug development. Prior to joining us, Dr. Dai worked at uniQure NV, a gene therapy company, from November 2015 to March 2018, where he most recently served as Senior Director of Process and Analytical Development. Prior to his time at uniQure, he served as the Head of Process Development Commercial Support at Shire Pharmaceuticals from 2009 to 2015 and held senior CMC roles at ImmunoGen, Inc., a biotechnology company, prior to that. Dr. Dai received an M.S. in biochemistry and molecular biology and a B.S. in Biochemistry from Peking University and a Ph.D. in biochemistry and molecular biology from Chinese Academy of Sciences. He completed his postdoctoral research at Harvard University.

What is the salary of Yong Dai?

As the Chief Technology Officer of Prevail Therapeutics Inc, the total compensation of Yong Dai at Prevail Therapeutics Inc is $1,349,040. There are 2 executives at Prevail Therapeutics Inc getting paid more, with Asa Abeliovich having the highest compensation of $2,861,680.

How old is Yong Dai?

Yong Dai is 49, he's been the Chief Technology Officer of Prevail Therapeutics Inc since 2019. There are 9 older and 3 younger executives at Prevail Therapeutics Inc. The oldest executive at Prevail Therapeutics Inc is Franz Hefti, 72, who is the Chief Development Officer.

What's Yong Dai's mailing address?

Yong's mailing address filed with the SEC is C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK, NY, 10016.

Insiders trading at Prevail Therapeutics Inc

Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over $0 worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth $816,407,705 . The most active insiders traders include Acquisition Corp Eli Lilly ..., Peter A. Thompson und Advisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of $138,767,762. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth $771,407,753.

What does Prevail Therapeutics Inc do?

Prevail Therapeutics Inc executives and stock owners

Prevail Therapeutics Inc executives and other stock owners filed with the SEC include:

• Asa Abeliovich,
  President, Chief Executive Officer, Director
• Jeffrey Sevigny,
  Chief Medical Officer
• Yong Dai,
  Chief Technology Officer
• Franz Hefti,
  Chief Development Officer
• Francois Nader,
  Independent Chairman of the Board
• Timothy Adams,
  Independent Director
• Morgan Sheng,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Carl Gordon,
  Director
• Peter Thompson,
  Independent Director
• William Carson,
  Director
• Emily Minkow,
  Chief Business Officer
• Kira Schwartz,
  General Counsel
• Brett Kaplan,
  Chief Financial Officer
• Advisors Llc Orbi Med Capit...,
  
• Acquisition Corp Eli Lilly ...,